Sermorelin 5 mg

Sermorelin acetate 5 mg is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) designed to stimulate the pituitary gland to increase endogenous growth hormone (GH) secretion. Formulated as a white to off-white lyophilized powder for reconstitution, each 5 mg vial contains sterile Sermorelin acetate intended for subcutaneous administration after dilution with an appropriate diluent.

Key features:

• Active ingredient: Sermorelin acetate (5 mg per vial)
• Mechanism: Mimics the biologically active fragment of GHRH to bind pituitary GHRH receptors and promote pulsatile release of endogenous GH and downstream insulin-like growth factor 1 (IGF-1)
• Presentation: Lyophilized powder in a single-dose vial for reconstitution
• Stability: Store refrigerated; protect from light and moisture. Reconstituted solution should be used within recommended time and storage conditions (follow clinical guidance)

Intended effects and clinical profile:

• Promotes physiologic, pulsatile increases in endogenous GH rather than providing exogenous GH
• May support improvements in body composition (reduced fat mass, increased lean mass), energy, recovery, and metabolic function in appropriate therapeutic contexts
• Results are gradual and depend on pituitary responsiveness; therapeutic outcomes often require sustained, supervised administration and monitoring

Administration and dosing (general profile):

• Administered by subcutaneous injection following reconstitution; dosing regimens vary by clinical objective and patient factors
• Typically prescribed and titrated by a qualified clinician based on baseline GH/IGF-1 levels, response, and safety monitoring
• Not intended for unsupervised use—requires medical evaluation, prescription, and follow-up

Safety and monitoring:

• Common effects may include injection-site reactions, transient flushing, headache, or mild edema
• Contraindications and precautions include active malignancy, proliferative diabetic retinopathy, uncontrolled diabetes, and hypersensitivity to components
• Requires monitoring of glucose metabolism, IGF-1 levels, and overall pituitary/adrenal function as clinically indicated
• Interactions: may affect or be affected by agents that alter GH/IGF-1 axis or pituitary function